Molecule
Aficamten is a prescription medicine indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. It is available as tablets for oral use. MedsAcross supplies Aficamten for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Source: US FDA prescribing information
Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity. Aficamten reduces the force generated by myosin at the cardiac sarcomere, which contributes to the pathophysiology of HCM. In patients with HCM, myosin inhibition with aficamten reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
Source: US FDA prescribing information
Recommended starting dose is 5 mg orally once daily. Dosage is individualized based on echocardiographic assessments and clinical status. Refer to Full Prescribing Information for instructions on dosage modification.
Source: US FDA prescribing information
MYQORZO is contraindicated with concomitant use of rifampin. Rifampin
Source: US FDA prescribing information
Boxed warning (risk of heart failure myqorzo): reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Risk of Heart Failure: Consider decreasing dose or dose interruption in patients with serious intercurrent illness. Drug Interactions Leading to Increased Risk of Heart Failure or Loss of Effectiveness: Advise patients of the potential for drug interactions.
Source: US FDA prescribing information
The following adverse reaction is discussed in other sections of labeling: Heart Failure The most common adverse reaction was hypertension (8%).
Source: US FDA prescribing information
Drugs that inhibit multiple pathways of MYQORZO elimination, strong CYP2C9 inhibitors, or moderate-to-strong CYP3A inducers may increase risk of heart failure. MYQORZO dose reduction and additional monitoring may be required when initiating or discontinuing these drugs. 7.1. Potential for Other Drugs to Affect Plasma Concentrations of MYQORZO Aficamten is primarily metabolized by CYP2C9 and, to a lesser extent by CYP3A, CYP2D6, and CYP2C19. Concomitant administration of drugs that inhibit multiple P450 pathways of aficamten elimination, strong inhibitors of CYP2C9, and moderate-to-strong inducers of CYP3A, may affect the exposure of aficamten.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Aficamten, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Myqorzo 10 mg tabletOral | Cytokinetics | US FDA | Available on request |
| Myqorzo 15 mg tabletOral | Cytokinetics | US FDA | Available on request |
| Myqorzo 20 mg tabletOral | Cytokinetics | US FDA | Available on request |
| Myqorzo 5 mg tabletOral | Cytokinetics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 4 presentations of Aficamten and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Aficamten, including Myqorzo.
Yes. The US FDA first approved Aficamten on 19 December 2025, according to Drugs@FDA.
Yes. Aficamten has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Aficamten is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.